Cramer's 'Mad Money' Follow-Up: Nov. 3

Every night on "Mad Money," Jim Cramer offers market commentary and general investment advice, and he makes calls on specific stocks, both of his own choosing and in response to viewer requests. He relies on his many years of experience and strong track record, and he takes full responsibility for his calls.

"I never shirk from admitting my mistakes; instead, I dwell on them to learn from them. I change my mind, I take losses, I own up to them," Cramer has said.

Here we track some of his calls from the previous episode of "Mad Money" and find out, at least in the very short term, how the stocks are performing. Keep in mind that Cramer might not have been recommending that viewers take immediate action on a stock. And, of course, it's up to the individual investor to do his or her own homework.

That said, here's how some of the stocks that Cramer talked about on Monday's "Mad Money" show fared today.

---

Jarden (JAH Quote): Cramer spoke with Chairman and CEO Martin Franklin, who said Jarden plans to expand its brand portfolio, which includes Sunbeam, Oster and Mr. Coffee, to the juvenile and over-55 markets, as well as internationally.

On Tuesday, Jarden closed up 32 cents, or 1.2%, at $26.62.

Pfizer(PFE Quote): Cramer recommended Pfizer, which Cramer's disliked in the past, and Bristol-Myers Squibb (BMY Quote) as defensive cancer drug stocks. He owns Bristol for his Action Alerts PLUS charitable trust, and he said that stock is his favorite of his two, citing its strong third-quarter sales and earnings growth as well as its yield. Cramer said Pfizer's Wyeth acquisition has turned it into a "whole new drug company." He said both stocks were at a good entry point.